Recent studies have identified a specialized subset of CD31 hi endomucin hi (CD31 hi EMCN hi ) vascular endothelium that positively regulates bone formation. However, it remains unclear how CD31 hi EMCN hi endothelium levels are coupled to anabolic bone formation. Mice with an osteoblast-specific deletion of Shn3, which have markedly elevated bone formation, demonstrated an increase in CD31 hi EMCN hi endothelium. Transcriptomic analysis identified SLIT3 as an osteoblast-derived, SHN3-regulated proangiogenic factor. Genetic deletion of Slit3 reduced skeletal CD31 hi EMCN hi endothelium, resulted in low bone mass because of impaired bone formation and partially reversed the high bone mass phenotype of Shn3 −/− mice. This coupling between osteoblasts and CD31 hi EMCN hi endothelium is essential for bone healing, as shown by defective fracture repair in SLIT3-mutant mice and enhanced fracture repair in SHN3-mutant mice. Finally, administration of recombinant SLIT3 both enhanced bone fracture healing and counteracted bone loss in a mouse model of postmenopausal osteoporosis. Thus, drugs that target the SLIT3 pathway may represent a new approach for vascular-targeted osteoanabolic therapy to treat bone loss.
I t is increasingly appreciated that the ancillary cell types present in bone tissue actively participate in osteogenesis. For example, a subset of CD31 hi , endomucin hi (EMCN hi ) vascular endothelium has been recently identified as residing in the bone marrow (BM) near the growth plate. CD31 hi EMCN hi endothelium is believed to actively direct bone formation, because alterations in CD31 hi EMCN hi endothelium impact bone architecture, bone formation and numbers of osteoprogenitors present in the marrow 1, 2 . CD31 hi EMCN hi endothelium levels can be altered by platelet-derived growth factor type BB (PDGF-BB), providing a potential link between bone resorption activity by osteoclasts and CD31 hi EMCN hi endothelium 3 . However, it is currently unclear whether and how levels of CD31 hi EMCN hi endothelium are coupled with the physiological need for bone formation and whether osteoblasts participate in this regulation.
Previously, we demonstrated that the adaptor protein Schnurri3 (SHN3) is a suppressor of osteoblast activity, because mice lacking SHN3 display a progressive increase in postnatal bone mass because of augmented bone formation 4, 5 . Because deletion of Shn3 in osteoblast-lineage cells is sufficient to greatly enhance bone formation, it appears that osteoblasts are able to coordinate all of the various tissue activities beyond osteoblast-mediated matrix secretion needed to form mature bone. Given the substantial osteoblast-intrinsic augmentation of bone formation in SHN3-deficient mice, we believed that this mouse strain represented an ideal opportunity to study how osteoblasts induce changes in their supporting cell lineages to facilitate bone formation.
In this article, we show that CD31 hi EMCN hi skeletal vasculature is present at greater levels in mice with an inducible deletion of Shn3 in osteoblasts and demonstrate that CD31 hi EMCN hi endothelium is regulated by osteoblasts. We further identify the secreted ligand SLIT3 as a novel SHN3-controlled, osteoblast-derived regulator of CD31 hi EMCN hi endothelium levels. SLIT3 belongs to a conserved family of three SLIT ligands that were initially discovered in the context of central nervous system development, where they mediate axonal guidance through the Roundabout (ROBO) family of receptors (ROBO1-ROBO4) 6, 7 . Subsequent studies showed that SLITs are widely expressed, and the SLIT-ROBO pathway has been implicated in multiple physiological functions outside of the nervous system, such as angiogenesis/vasculogenesis [8] [9] [10] , stem cell regulation 11, 12 and cancer development 13 . In addition, SLIT3 has been identified as a proangiogenic factor in mouse models and human engineered tissue 14, 15 . However, the role of SLIT3 in bone metabolism is still largely unclear.
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SHN3 acts in osteoblasts to regulate CD31 hi EMCN hi endothelium.
To address our hypothesis that osteoblasts are able to coordinate levels of osteogenic CD31 hi EMCN hi endothelium to maintain bone formation capacity, we assessed CD31 hi EMCN hi endothelium levels in a mouse strain displaying augmented postnatal bone formation, namely, Shn3 −/− mice. We found that CD31 and EMCN double-positive endothelium was present in the marrow immediately beneath the growth plate and was considerably higher in Shn3 −/− mice than in wild-type (WT) controls. This effect was bone specific because, relative to littermate controls, Shn3 −/− mice displayed normal levels of EMCN + vessels in other organs, including heart, brain, lung and kidney ( Supplementary Fig. 1a ). This vessel phenotype was present in neonatal Shn3 −/− mice and thus preceded the appearance of the high bone mass phenotype 5 (Supplementary Fig. 1b ). Flow cytometry also confirmed greater amounts of CD31 hi EMCN hi vascular endothelium in the bones of Shn3 −/− mice than in WT littermate controls (Fig. 1e,f and Supplementary Fig. 1c ). Taken together, these observations suggest that SHN3 regulates levels of skeletal CD31 hi EMCN hi endothelium in addition to its role in regulating osteoblast activity.
Because SHN3 acts in a cell-intrinsic manner to regulate bone formation by osteoblasts, we reasoned that SHN3 also acts in osteoblasts to control levels of CD31 hi EMCN hi endothelium. To test this directly, we bred Shn3 f/f mice to a cre-deleter strain targeting osteoblast progenitors, OSX-cre, and to a cre-deleter strain targeting mature osteoblasts, DMP1-cre. Both Shn3 osx and Shn3 dmp1 male mice exhibited a similar degree of higher bone mass relative to littermate Shn3 f/f controls, including greater cortical bone thickness, largely recapitulating the characteristic bone phenotype of Shn3 −/− mice ( Fig. 2a,b and Supplementary Fig. 2a-c) . On the basis of this, we selected the Shn3 dmp1 strain for further study because it implicates a more restricted subpopulation in any phenotypes observed 16, 17 . Histomorphometric analysis confirmed that the high bone mass phenotype of Shn3 dmp1 mice was due to augmented osteoblastmediated bone formation predominantly on the endosteal surface ( Fig. 2c,d and Supplementary Fig. 2d,e ). Analysis of skeletal CD31 hi EMCN hi endothelium by both immunostaining and flow cytometry demonstrated that Shn3 dmp1 mice displayed higher levels of this subset of endothelial cells relative to littermate Shn3 f/f controls in a similar manner as seen in Shn3 −/− mice ( Fig. 2e-g and Supplementary Fig. 2f-h) .
To further confirm that the function of SHN3 to regulate skeletal CD31 hi EMCN hi vascular endothelium maps to osteoblasts, we generated endothelial cell-specific Shn3-deficient mice (Shn3 cdh5 mice) using the Cdh5 (VE-cadherin)-Cre. Despite observing efficient deletion of Shn3 in BM endothelial cells ( Supplementary  Fig. 2i ), levels of CD31 hi EMCN hi endothelial cells were unchanged in Shn3 cdh5 mice relative to littermate Shn3 f/f controls ( Supplementary  Fig. 2j-m) . Accordingly, Shn3 cdh5 mice also displayed normal bone mass relative to littermate Shn3 f/f controls ( Supplementary Fig. 2n ). Taken together with the Shn3 −/− and Shn3 dmp1 phenotype, we conclude that osteoblasts regulate skeletal CD31 hi EMCN hi vascular endothelium in an SHN3-dependent manner and that SHN3 does not act directly in endothelial cells to regulate skeletal phenotypes.
To determine whether osteoblasts continuously participate in this regulation or whether this process is limited to embryonic development, we intercrossed Shn3 f/f mice with osteocalcin-CreERT mice expressing a tamoxifen-activated Cre recombinase in mature osteoblasts under the control of the osteocalcin promoter (Shn3 ocn-ert mice). Supplementary  Fig. 2o ). Thus, mature osteoblasts continuously participate in tuning the levels of CD31 hi EMCN hi endothelium in bone, and this coupling is not solely a developmental phenomenon.
SHN3 regulates Slit3 expression in osteoblasts.
To investigate whether the regulation of marrow angiogenesis by SHN3 is a direct effect of osteoblasts on endothelial cells, we harvested conditioned medium from WT and Shn3 −/− primary osteoblasts and introduced to cultures of primary BM-derived endothelial cells. Conditioned medium from Shn3 −/− primary osteoblasts displayed an enhanced ability relative to conditioned medium from WT osteoblasts to induce endothelial migration and capillary tube formation, suggesting that the relevant mediator is a soluble osteoblast-derived factor ( Fig. 3a-d ). To identify potential proangiogenic factors regulated by SHN3 in osteoblasts, we performed RNA-sequencing (RNA-seq) transcriptional profiling. Gene Ontology (GO) analysis demonstrated that the set of differentially expressed genes (DEGs) in Shn3 −/− versus WT osteoblasts is enriched for genes mediating angiogenesis in addition to the expected enrichment for genes involved with bone development and mineralization ( Fig. 3e ).
Examination of the expression of a number of proangiogenic factors revealed that only SLIT3, a soluble axonal chemorepellent recently shown to have angiogenic functions, showed substantially greater levels in Shn3 −/− osteoblasts ( Fig. 3f ) 3, 14 . Further expression analysis confirmed robust Slit3 expression in osteoblasts and demonstrated negligible Slit3 expression in osteoclasts ( Supplementary  Fig. 3a ,b) 18 . Similarly, immunofluorescence for beta-galactosidase in Slit3 +/− mice 19 bearing a targeted insertion of an LacZ cassette into the Slit3 locus identified SLIT3 expression in cells adjacent to the bone surface consistent with osteoblasts ( Supplementary Fig. 3c ). Similarly, human mesenchymal stromal cell-derived osteoblasts also expressed Slit3 ( Supplementary Fig. 3d ). To verify that Slit3 expression is augmented in Shn3 −/− osteoblasts relative to WT controls, we used three complementary approaches. First, real-time PCR was used to validate the higher levels of Slit3 observed by RNA-seq ( Fig. 3g ). Second, overexpression or knockdown of Shn3 in human mesenchymal stem cell (hMSC)-derived osteoblasts demonstrated, respectively, a suppression or an enhancement of both mRNA and protein levels of Slit3 (Fig. 3h ,i). Moreover, overexpression of Shn3 in murine primary osteoblasts also dramatically reduced SLIT3 expression ( Supplementary Fig. 3e ). Lastly, ELISA demonstrated threefold higher SLIT3 secretion in conditioned medium from Shn3 −/− osteoblasts relative to WT controls ( Fig. 3j ). Thus, SHN3 is a negative regulator of SLIT3 expression in osteoblasts.
Recent studies have shown that preosteoclast-derived PDGF-BB is able to induce CD31 hi EMCN hi endothelium in bone 3 . We were unable to detect PDGF-BB secretion by osteoblasts, and negligible Pdgfb mRNA was observed in both WT and Shn3 −/− osteoblasts ( Fig. 3f and Supplementary Fig. 3f ). In addition, serum PDGF-BB levels were unaltered in Shn3 −/− mice ( Supplementary Fig. 3f ). Thus, we do not observe evidence of regulation of PDGF-BB by SHN3.
SHN3 acts predominantly by regulating ERK activity, as mice bearing a knockin of a mutation in three amino acids comprising the ERK interacting motif (Shn3 KI/KI mice) in SHN3 largely recapitulate the high bone mass phenotype of Shn3 −/− mice 4 . Slit3 levels were also higher in primary Shn3 KI/KI osteoblasts relative to WT controls (Fig. 3k ), and treatment with the ERK pathway inhibitor trametinib reduced Slit3 expression in both hMSC-derived osteoblasts and murine primary calvarial osteoblasts relative to vehicle ( Fig. 3l and Supplementary Fig. 3g ). Consistent with these observations, Shn3 KI/KI mice also displayed greater levels of CD31 hi EMCN hi skeletal endothelium, a phenotype similar to that seen in Shn3 −/− mice ( Fig. 3m ). Thus, SHN3 regulates SLIT3 expression and CD31 hi EMCN hi endothelium levels via its ability to bind and regulate ERK.
SLIT3 acts downstream of SHN3 to promote CD31 hi EMCN hi endothelium formation and bone formation in vivo.
To determine whether SLIT3 contributes to the regulation of BM endothelium by osteoblasts in vitro, we conducted a dose-response curve for SLIT3 treatment as described in prior studies 14, 20, 21 . BM endothelial progenitor outgrowth cells (EPOCs) treated with recombinant SLIT3 displayed enhanced migration and tube formation relative to a vehicle control (Fig. 4a,b and Supplementary Fig. 4a ). In addition, SLIT3 resulted in modestly higher levels of proliferation in BM-derived EPOCs, consistent with the activity of SLIT3 observed in nonskeletal vascular endothelium 14 ( Supplementary  Fig. 4b ). SLIT1 and SLIT2 displayed a similar ability to promote tube formation relative to vehicle, consistent with observations that each of the SLITs displays a similar capacity for ROBO binding and activation 9, 22, 23 ( Supplementary Fig. 4c,d ). Next, conditioned medium was collected from WT and Shn3 −/− osteoblasts, and placed on BM-derived endothelial cells together with an anti-SLIT3 blocking antibody or an isotype control. Enhanced tube formation was seen with conditioned medium from SHN3deficient osteoblasts, and treatment with an anti-SLIT3 blocking antibody abrogated this effect ( Fig. 4c,d ). Investigation of the signaling pathways downstream of SLIT3 in BM endothelial cells demonstrated activation of ERK mitogen-activated protein kinase and Hippo signaling, pathways known to participate in angiogenesis ( Supplementary Fig. 4e ) 24, 25 . Interestingly, we also noted that treatment of BM-derived endothelial cells with SLIT3 enhanced the acquisition of a CD31 hi EMCN hi surface immunophenotype in culture ( Supplementary Fig. 4f ). Similarly, systemic administration of SLIT3 resulted in greater levels of skeletal CD31 hi EMCN hi endothelium production in vivo ( Supplementary Fig. 4g ). In addition, SLIT2 augmented formation of CD31 hi EMCN hi endothelium in vivo relative to vehicle, suggesting that other SLITs are also capable of eliciting this response ( Supplementary Fig. 4h ). Thus, SLIT3 is both necessary and sufficient to mediate osteogenesis by regulating production of CD31 hi EMCN hi endothelium.
To assess whether SLIT3 regulates CD31 hi EMCN hi endothelium under physiological conditions, we performed immunofluorescence and flow cytometry on Slit3 −/− mice, with both approaches revealing a reduction in CD31 hi EMCN hi skeletal endothelium ( Fig. 4e -h). Concurrent with this reduction in CD31 hi EMCN hi endothelium, Slit3 −/− mice showed a substantial reduction in both total bone mass and cortical bone thickness relative to WT littermates ( Fig. 4i -k). Consistent with prior reports 19 , Slit3 −/− mice displayed a decrease in body weight at 1 month of age, with body weight normalization occurring by 3 months of age ( Supplementary  Fig. 5a ). Thus, osteopenia could be observed even at ages where the weight of Slit3 −/− mice was indistinguishable from that of littermate controls. This osteopenia was due to reduced osteoblast activity, because bone formation was reduced without substantial alterations in osteoclast numbers or serum levels of cross-linked C-telopeptide of type I collagen (CTX), a marker of osteoclast activity (Fig. 4l ,m and Supplementary Fig. 5b ,c). To evaluate whether this reduction in bone formation was due to cell-intrinsic defects in osteoblast activity, we examined the differentiation of SLIT3-deficient osteoblasts. Mineralization activity, alkaline phosphatase (ALP) induction, and induction of characteristic osteoblast transcripts were all intact or even slightly enhanced in the absence of SLIT3 ( Supplementary  Fig. 5d-f ). Furthermore, treatment of osteoblasts with recombinant SLIT3 did not enhance osteoblast activation relative to vehicle, nor did treatment with a ROBO1-Fc fusion that blocks SLIT signaling impair osteoblast differentiation ( Supplementary Fig. 5g,h) . Thus, the ability of SLIT3 to enhance bone formation in vivo is not attributable to the direct effects of SLIT3 on osteoblasts, which is consistent with the model that SLIT3 directly augments levels of CD31 hi EMCN hi endothelium to augment bone formation. To confirm whether osteoblasts represent the key cellular source of SLIT3 controlling levels of skeletal CD31 hi EMCN hi endothelium and bone mass accrual in vivo, we generated mice bearing a conditional Slit3 floxed allele (Slit3 f/f mice) and validated their deletion capacity ( Supplementary Fig. 6a ). We bred Slit3 f/f mice to cre-deleter strains targeting either osteoblast progenitors via OSX-cre or mature osteoblasts via DMP1-cre. Osteoblast-specific deletion of Slit3 in vivo recapitulated both the impaired CD31 hi EMCN hi endothelium levels and the osteopenia phenotypes observed in Slit3 −/− mice ( Fig. 5a-d and Supplementary Fig. 6b-e ). Furthermore, neither neuron-specific deletion of Slit3 by using Synapsin-cre nor specific deletion of Slit3 in endothelial cells by using Cdh5-cre in vivo led to detectable bone loss ( Supplementary Fig. 6f ,g). Thus, osteoblasts are the key functional source of SLIT3 influencing skeletal biology. We next questioned whether the enhanced production of SLIT3 by SHN3-deficient osteoblasts contributes to the high bone mass phenotype of SHN3-deficient mice. To address this, we performed a genetic interaction study by intercrossing Shn3 −/− and Slit3 −/− mice.
As shown in Fig. 4 , an epistatic genetic interaction was observed between Shn3-and Slit3-null alleles, because the higher bone formation, trabecular bone mass, and CD31 hi EMCN hi endothelial cell levels in Shn3 −/− mice were partially reversed in Shn3 −/− Slit3 −/− mice. Thus, SLIT3 contributes to both the high bone mass phenotype and enhanced CD31 hi EMCN hi endothelium phenotype of SHN3deficient mice in vivo. In addition, a genetic interaction similar
branch per field Mean no. branch per field to that observed with the Shn3 and Slit3 germline null alleles was recapitulated using conditional deletion of Shn3 and Slit3 alleles in osteoblasts using Osx-cre ( Supplementary Fig. 7a,b ). Thus, the interaction between Shn3 and Slit3 alleles to regulate bone mass is intrinsic to osteoblasts. Taken together, these results imply that SLIT3 production is used by osteoblasts to condition their environment through angiogenesis to be conducive for bone formation.
ROBO1 is a key receptor for SLIT3 on marrow endothelial cells.
Because SLITs are known to signal through ROBO1-ROBO4, we next explored which ROBO receptors might be acting in endothelial cells to mediate the response to SLIT3 26 . CD31 hi EMCN hi skeletal endothelial cells were isolated by FACS and subjected to RNA-seq transcriptome analysis, revealing that Robo1 and Robo4 are the predominant ROBO family receptors expressed ( Supplementary  Fig. 8a ). Immunofluorescence for beta-galactosidase in the bones of Robo1 +/− mice bearing a knockin of an LacZ cassette into the Robo1 locus confirmed that Robo1 expression is present in endothelium near the growth plate, a localization consistent with CD31 hi EMCN hi endothelial cells ( Supplementary Fig. 3c ). We also characterized ROBO expression in other skeletal cell types, indicating that osteoblasts express Robo1 and Robo2, whereas osteoclasts show negligible expression of ROBO family members ( Supplementary Fig. 8b,c) . Given the expression of Robo1 and Robo4 in CD31 hi EMCN hi endothelial cells, the skeletal phenotype of Robo1 −/− and Robo4 −/− mice was examined.
Robo1 −/− , but not Robo4 −/− , mice display low trabecular bone mass in long bones relative to WT controls ( Fig. 5e and Supplementary Fig.  8d ,e), and Robo1 −/− mice also showed lower levels of CD31 hi EMCN hi skeletal endothelium ( Fig. 5f and Supplementary Fig. 8f ). Robo2 expression was not detected in either sorted CD31 hi EMCN hi skeletal endothelial cells or cultured BM-derived endothelial cells, and Robo2 expression was not induced by either germline Robo1 deficiency or shRNA-mediated Robo1 knockdown ( Supplementary Fig. 8g -i). Thus, no evidence of ROBO2-medaited compensation for ROBO1 loss of function was observed. Next, the mechanism of SLIT3-mediated effects on BM endothelial cells was investigated. Knockdown of Robo1 in BM-derived endothelial cells impaired their response to SLIT3 relative to an irrelevant shRNA control as determined by both their tube formation capacity and phosphorylation of the hippo pathway signaling intermediate YAP ( Supplementary Fig. 9a,b ). YAP has been reported to play a crucial role in endothelial cell migration and tube formation 25, 27 . Consistent with this, relative to an irrelevant shRNA control, shRNA-mediated knockdown of YAP considerably reduced the ability of SLIT3, but not FGF2, to induce tube formation in BM-derived endothelial cells, indicating that YAP acts downstream of the SLIT3-ROBO1 pathway to control tube formation ( Supplementary Fig. 9c,d) . Taken together, ROBO1 is a key receptor controlling both endothelial cell responses to SLIT3 and overall bone mass accrual. An SHN3/SLIT3 osteoblast-endothelium coupling pathway plays an essential role in fracture healing. Given that bone repair is accompanied by extensive elaboration of new blood vessels, we hypothesized that the SHN3-SLIT3 pathway-mediated communication between osteoblasts and endothelial cells may be vital for bone fracture healing. In support of this hypothesis, immunohistochemical analysis of human fracture callus tissue demonstrated robust expression of SLIT3 in osteoblasts and the presence of CD31 + endothelium in physical proximity to osteoblasts ( Supplementary  Fig. 10a,b ). An open femoral midshaft fracture model was established and used to study bone healing in Shn3 −/− , Slit3 −/− , Shn3 −/− Slit3 −/− and WT control mice. Twenty-one days postfracture, we performed micro computed tomography (µ CT) and histology analysis and found that fracture healing was enhanced in Shn3 −/− mice. Relative to WT controls, the fracture site in Shn3 −/− mice displayed extensive bridging with mature lamellar bone that had already remodeled to contain marrow elements within the newly formed callus tissue. In contrast, deletion of Slit3 led to complete non-union and arrest of fracture healing with only trace amounts of cartilaginous callus present relative to WT controls (Fig. 6a-c) . Consistent with the results of the bone mass genetic interaction studies, SLIT3 deficiency largely reversed the enhanced healing phenotype of SHN3deficient mice. These observations of enhanced and impaired healing in SHN3-deficient and SLIT3-deficient mice, respectively, translated into improved or impaired biomechanical properties of the callus, as shown by the load to failure or maximum load sustained across the fracture site. Consistent with observations in basal bone mass phenotypes, Shn3 −/− mice displayed enhanced angiogenesis throughout the callus relative to WT controls, and this phenotype was reversed by SLIT3 deficiency (Fig. 6d,e and Supplementary  Fig. 10c,d) . Thus, the coupling between osteoblasts and vascular endothelium mediated by the SHN3-SLIT3 pathway is essential for fracture healing.
SLIT3 has therapeutic effects in models of fracture healing and postmenopausal osteoporosis. Because SLIT3-mediated crosstalk between osteoblasts and CD31 hi EMCN hi endothelium is an important regulator of bone mass accrual and bone fracture healing, we hypothesized that administration of exogenous SLIT3 may have therapeutic effects to promote bone formation and regeneration. To examine this, we administered recombinant SLIT3 twice weekly via intravenous (i.v.) injection in 5-week-old male mice concurrent with performing an open femoral midshaft fracture. After 21 days of treatment, µ CT and histological analysis showed an enhancement of bone fracture healing in SLIT3-treated mice (Fig. 6f,g) . The bone volume in the callus area was greater by almost twofold relative to controls (Fig. 6h ). Furthermore, vascularization of the fracture callus was also augmented by SLIT3 administration relative to vehicle ( Fig. 6i and Supplementary  Fig. 10e ). Finally, biomechanical testing demonstrated that SLIT3 treatment considerably enhanced the maximum load sustained and stiffness of the fracture callus, demonstrating improvements in clinically meaningful endpoints (Fig. 6j) . Notably, examination of vascular morphology did not detect alterations in lung, heart, kidney or retina, and no changes in brain ultrastructure were present after SLIT3 administration ( Supplementary Fig. 11a-d) .
Thus, under this dosing strategy and with regard to these endpoints, the effects of SLIT3 were specific to bone. Nevertheless, because SLIT3 can affect a wide variety of tissues, it is important to anticipate potential extraskeletal toxicities of SLIT3 therapy. As a proof-of-principle strategy to avoid potential extraskeletal toxicities, local delivery of SLIT3 into a fracture site was achieved with a SLIT3-loaded collagen sponge. This approach recapitulated the effects of systemic SLIT3 delivery in promoting fracture healing as judged by improved mineralization and biomechanical properties of the fracture callus and augmented formation of CD31 hi EMCN hi endothelium relative to either no sponge or implantation of a sponge without SLIT3 (Fig. 6k,l and Supplementary Fig. 11e ). Local delivery of SLIT3 also did not impact non-skeletal vascular abundance or morphology or brain ultrastructure ( Supplementary Fig. 11f-h) .
Given the therapeutic effects of SLIT3 in a fracture model, we next examined whether systemic SLIT3 administration can protect from bone loss in the murine ovariectomy (OVX) model of postmenopausal osteoporosis 28 . Successful OVX was confirmed 2 months after OVX by the presence of both osteopenia and uterine atrophy ( Fig. 6m and Supplementary Fig. 12a,b) . First, the ability of SLIT3 to prevent bone loss was examined in this model. Mice were treated with i.v. injection of SLIT3 or vehicle twice weekly initiated 2 weeks after OVX. μ CT analysis showed that SLIT3 administration substantially countered OVX-induced bone loss as shown by greater trabecular bone volume/total volume (BV/TV) and cortical thickness ( Fig. 6m and Supplementary Fig. 12c ). Because the effects of SLIT3 were comparable with the effects of parathryoid hormone (PTH) treatment, this suggests that the magnitude of SLIT3 effect is clinically significant. Moreover, both SLIT3 and PTH administration reversed the attenuation of endosteal CD31 hi EMCN hi endothelium occurring after OVX and similarly rescued endosteal bone formation ( Supplementary Fig. 12d-f ). To further investigate the therapeutic activity of SLIT3, we examined the ability of SLIT3 to promote bone formation after the onset of OVX-induced osteopenia. Mice were treated with i.v. injection of SLIT3 or vehicle twice weekly initiated 8 weeks after OVX surgery. SLIT3 administration substantially reversed bone loss as shown by greater trabecular BV/TV and cortical thickness ( Supplementary  Fig. 12g,h) . Furthermore, SLIT3 administration considerably augmented the amount of CD31 hi EMCN hi endothelial cells in this context ( Supplementary Fig. 12i,j) . Taken together, these results provide proof of principle that SLIT3 may have clinical utility to enhance fracture healing and to treat disorders of low bone mass such as postmenopausal osteoporosis.
Discussion
Even though bone formation is mediated solely by osteoblasts, it is likely that many other tissue types present in bone, such as vascular endothelium or autonomic and sensory nerves, contribute to creating a conducive milieu for bone formation 1,2,29-31 . To the degree that the creation of a local osteogenic milieu should be coordinated with the cell-intrinsic matrix production capacity of osteoblasts,
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Non-union d Shn3 +/+ Slit3 +/+ it would be mechanistically attractive for osteoblasts to regulate their own matrix production alongside the activities of these supporting cell types. However, this remains a poorly understood facet of bone physiology. In this study, we hypothesized that mice with extreme increases in bone formation represent an opportunity to identify how osteoblasts regulate supporting tissue types in bone to create a pro-osteogenic milieu. In particular, we used the greatly enhanced bone formation phenotype of mice lacking the adaptor protein SHN3 to identify that osteoblast-derived SLIT3 enhances levels of an osteogenic subtype of vascular endothelium in bone, CD31 hi EMCN hi endothelium. Accordingly, mice lacking SLIT3 or the known SLIT receptor ROBO1 display reduction in both the levels of marrow CD31 hi EMCN hi endothelium and basal bone mass. Support for osteoblasts being a key source of SLIT3 in bone include the observation of robust and specific SLIT3 expression in osteoblasts, without appreciable SLIT3 expression in osteoclasts or CD31 hi EMCN hi endothelium. Conditional deletion of Shn3 in late-stage osteoblasts enhanced SLIT3 expression and CD31 hi EMCN hi endothelium levels, and osteoblast-derived conditioned medium enhanced BM endothelial tube formation in a SLIT3-dependent manner. Moreover, genetic interaction studies demonstrated that the CD31 hi EMCN hi endothelium-promoting and enhanced bone formation effects of SHN3 deficiency are partially SLIT3 dependent. This rescue of the SHN3 phenotype is not a generic property of crossing SHN3 to a mouse with low bone mass, because crossing the Shn3 −/− mouse strain to the osteopenic Rsk2 −/− strain did not substantially alter the Shn3 −/− phenotype 4 . Thus, the epistatic interaction between Shn3 and Slit3 alleles in both regulation of bone mass and CD31 hi EMCN hi endothelium levels provides in vivo genetic evidence that SLIT3 is a critical effector downstream of SHN3, although it does not preclude the existence of additional effectors.
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In addition, ROBO1-deficient, but not ROBO4-deficient, mice show an osteopenic phenotype, and accordingly ROBO1 knockdown partially blocks BM endothelial responses to SLIT3. Although the phenotype of ROBO1-deficient mice and the in vitro studies indicate that it is a key receptor of SLIT signals in the regulation of bone mass accrual, it cannot be excluded that other SLIT-ROBO members similarly contribute in either an independent or a redundant manner 26 .
Flow cytometry analysis of CD31 hi EMCN hi endothelium suggests that this is a relatively rare population of cells, with only very limited numbers of cells present relative to other hematopoietic or mesenchymal lineages. This raises the question of how such a small population can exert such a large effect on organ physiology. One possible explanation is that the highest density of CD31 hi EMCN hi endothelium is observed at very active sites of bone formation, such as the primary spongiosum immediately adjacent to the growth plate of an actively growing long bone, and within this site CD31 hi EMCN hi endothelium is observed to be in close physical proximity with osteoblast-lineage cells. This physical proximity between CD31 hi EMCN hi endothelium and the osteoblast lineage cells they support may act to amplify each other's physiological effects. Further work is needed to clarify the nature and mediators of these interactions beyond SLIT3. In addition, much remains to be learned about properties that define CD31 hi EMCN hi endothelium, including how this population relates to other endothelial cell types present in bone 32 .
Given the evidence that fracture healing is accompanied by extensive elaboration of new blood vessels, the role of SHN3/SLIT3mediated coupling between osteogenesis and CD31 hi EMCN hi endothelium was explored in bone regeneration and found to be critically important. Impaired fracture healing is observed in elderly patients, patients with systemic vascular diseases such as diabetes, patients with inflammatory disorders or chronic infection, or patients with large traumatic bone defects 33 . For these classes of patients, a single bone fracture often results in many years of pain, severely impaired mobility and numerous attempts at surgical management of their fracture. From this perspective, developing a means for medical therapy to promote fracture healing is urgently needed. Interestingly, the phenotypes observed with disruption of the SHN3/SLIT3 axis may extend beyond simply promoting more bone formation, because the fracture callus observed in SHN3deficient mice was markedly more mature, including displaying overall more mature lamellar bone in addition to enhanced recruitment of hematopoietic elements to the callus. Conversely, SLIT3deficient mice displayed an arrest at early stages of fracture callus maturation, displaying a lack of propagation of the mineralization sites on either side of the callus.
In this article, we also provide proof of principle for the potential of exogenous SLIT3 to promote bone fracture healing and prevent bone loss in a model of postmenopausal osteoporosis. Notably, these findings contrast with a prior in vitro study suggesting that SLIT2 suppresses osteoblast differentiation in vitro 34 . This result more broadly suggests that agents that target bone vasculature may represent a novel class of bone anabolics and raises the possibility that vascular-targeted anabolics may have a synergistic or complementary effect when used in combination with an osteoblast-targeted anabolic such as a PTH analogue or an anti-SOST antibody. Development of new categories of bone anabolic agents is especially important given the current limitations on the maximum duration of therapy with PTH-based anabolic agents. Likewise, in light of increasing evidence establishing that osteoporosis drugs can be used in a sequential or combination manner to obtain superior clinical outcomes, having therapeutic access to a larger diversity of anabolic pathways is highly desirable 35 . Notably, because the pharmacokinetics and pharmacodynamics of SLIT3 in vivo are not currently known, further enhancement of the magnitude of SLIT3 effect may be possible with optimization of dosing and delivery strategies.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0020-z.
Genetically modified mice. Shn3 −/− (BALB/c), Shn3 KI/KI (C57BL/6j), Shn3 floxed allele (C57BL/6j), Slit3 −/− (BALB/c), Robo1 −/− (ICR) and Robo4 −/− (C57BL/6j) mice were all previously reported, with Robo1 −/− mice being a generous gift from Dr. Marc Tessier-Lavigne 4, 7, 8, 14, 19, 36 . To generate Slit3 floxed mice, we obtained from the International Mouse Phenotyping Consortium the SLIT3-F08 mouse embryonic stem cell line in which exon 8 is flanked by loxP sites. After validation, F08 EC cells were injected into C57BL/6J blastocysts, and the derived chimeras displaying germline transmissions were selected for further breeding. The LacZ and neo cassettes were removed by intercrossing with transgenic mice expressing Flp recombinase. Slit3 floxed mice were backcrossed with C57BL/6j mice for eight generations.
Transgenic mice expressing Cre recombinase under control of the cdh5 promoter (cdh5-Cre) 37 , osterix promoter (osx-Cre) 38 , dmp1 promoter (dmp1-Cre) 39 and Osteocalcin-CreERT mice 40 were mated with Shn3 floxed or Slit3 floxed mice to obtain various Shn3 or Slit3 conditional knockout mice. For postnatal activation of CreERT, we intraperitoneally injected 100 mg kg −1 tamoxifen (Sigma) in corn oil (Sigma) to 1-month-old mice once a day for 5 consecutive days. Littermate controls were used for all experiments.
All animals were maintained in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and were handled according to protocols approved by the Weill Cornell Medical College subcommittee on animal care (Institutional Animal Care and Use Committee).
µCT analysis. µ CT analysis was conducted on a Scanco Medical µ CT 35 system at the Citigroup Biomedical Imaging Core using the previously described parameters 4 . µ CT analysis was performed by an investigator blinded to the genotypes of the animals under analysis.
Immunofluorescence, histology and histomorphometry. For immunofluorescence, fresh bone dissected and soft tissues from WT mice and mutant mice were collected and immediately fixed in ice-cold 4% paraformaldehyde solution for overnight. Decalcification was specially carried out with 0.5 M EDTA at 4 °C with constant shaking for bone samples from mice (age ≥ 1 week). All samples were embedded in OCT compound (Sakura) and cut into 25-μ m-thick sagittal sections using a cryostat (Leica). Immunofluorescence staining and analysis were performed as described previously 29, 41 . In brief, after treatment with 0.2% Triton X-100 for 10 min, sections were blocked with 5% donkey serum at room temperature for 30 min and incubated overnight at 4 °C with antibodies: CD31 (553370, 1:100; BD Pharmingen), CD31 conjugated to Alexa Fluor 488 (FAB3628G, 1:50; R&D Systems), Endomucin (sc-65495, 1:100; Santa Cruz), Neurofilament M Antibody (841001; BioLegend) or Beta Galactosidase antibody (GTX77365, 1:100; Gene Tex). Primary antibodies were visualized with species-appropriate Alexa Fluor-coupled secondary antibodies (1:400; Molecular Probes). Nuclei were counterstained with 4′ ,6-diamidino-2phenylindole (DAPI). Brian sections also were stained by Red Fluorescent Nissl (Thermo). All immunofluorescence experiments were confirmed by at least one independent repeat. An Olympus IX81 confocal microscope or Zeiss LSM-880 confocal microscope was used to image samples. Quantification of skeletal vasculature was performed as previously described 29 . In brief, the CD31 + or Endomucin-positive (red) area relative to the total BM area (visualized in blue) was calculated using ImageJ software (http://rsbweb.nih.gov/ij/).
For whole-mount immunostaining, retinas were collected from adult mice after systemic or local SLIT3 administration in bone fracture models. Immunofluorescence staining was performed as described previously 42 . Mice were intra-orbitally injected with an anti-VE-cadherin antibody (clone BV13; BioLegend).
For histological analysis, hind limbs were dissected from the mice or human callus, fixed in 10% neutral-buffered formalin for 24-48 h and decalcified by daily changes of 15% tetrasodium EDTA for 2 weeks. Tissues were dehydrated by passage through an ethanol series, cleared twice in xylene, embedded in paraffin, and sectioned at 7 µ m thickness. Decalcified sections were stained with hematoxylin and eosin (H&E). We incubated the slides with primary antibody to mouse EMCN (sc-65495, 1:200; Santa Cruz) and human Slit3 (ab198726, 1:50; Abcam) at 37 °C for 2 h and subsequently used a horseradish peroxidasestreptavidin detection system (Dako) to detect the immunoreactivity. We measured the number and volume of positively stained vessels in four random visual fields of callus in three sequential sections per mouse in each group.
For histomorphometry, mice were injected with calcein (25 mg kg −1 ; Sigma), and un-decalcified sections of the lumbar vertebrae were stained using von Kossa and TRAP as previously described 29 . Static and dynamic histomorphometric analysis was performed using the Osteomeasure Analysis System (Osteometrics) following standard nomenclature as previously described 43 . BV/TV, BFR/BS (µ m 3 µ m −1 yr −1 ), mineral apposition rate (µ m day −1 ), Ob.S/BS(%) and osteoclast number/bone perimeter were analyzed.
Flow cytometry and cell sorting. Femur and tibia were dissected from mutant mice and control groups after removing surrounding connective tissues. The metaphysis region and diaphysis regions of bone were crushed in Hank's Balanced Salt Solution (Life Technologies) containing 10 mM HEPES (pH 7.2) (CellGro) and enzymatically digested with 2.5 mg mL −1 Collagenase A (Roche) and 1 unit mL −1 Dispase II (Roche) for 15 min at 37 °C under gentle agitation. The resulting cell suspensions were filtered (40 µ m) and washed using PBS (pH 7.2) containing 0.5% BSA (Fraction V) and 2 mM EDTA. After washing, equal numbers of cells per mouse were blocked with Purified Rat Anti-Mouse CD16/ CD32 (BD Biosciences) for 30 min on ice, then stained with APC-conjugated EMCN antibody (50-5851-80; eBioscience), PE-conjugated CD31 (12-0311-81; eBioscience), FITC-conjugated CD45 (35-0451; Tonbo), APC/Cy7-conjugated Ter119 (116223; BioLegend) and PerCP/Cy5.5-conjugated CD146 (562231; BD Biosciences) for 45 min on ice. After washing, cells were resuspended in PBS (pH 7.2) with 2 mM EDTA and 1 µ g mL −1 DAPI (live/dead exclusion) for analysis on an LSRII flow cytometer system (BD Biosciences) cytometer and analyzed using FlowJo software (Tree Star). Cell sorting was performed with a FACSAria II SORP cell sorter (Becton Dickinson) at Weill Cornell Medical College, with exclusion of DAPI + cells and doublets. The strategy to sort CD31 hi EMCN hi endothelial cells is diagrammed in Supplementary Fig. 1c .
Osteoblast culture and differentiation assays. Primary calvarial osteoblasts were isolated from 5-day-old mice by triple collagenase/Dispase II digestion. Cells were cultured in α -MEM medium (Gibco) containing 10% FBS, 2 mM l-glutamine, 1% penicillin/streptomycin, 1% HEPES and 1% non-essential amino acids, and differentiated with ascorbic acid and β -glycerophosphate. Conditioned medium was collected from culture of primary osteoblasts and stocked at − 80 °C. hMSCs were cultured and differentiated into osteoblasts using a commercial kit (Cyagen). All cells were routinely tested to be mycoplasma negative.
For staining of extracellular matrix mineralization, cells were fixed with 10% neutral-buffered formalin and stained with alizarin red. Mineralization activity was measured by colorimetric analysis. For ALP activity, osteoblasts were fixed with 10% neutral formalin buffer and stained with the solution containing fast blue and naphthol (Sigma-Aldrich). Alternatively, osteoblasts were incubated with tenfold diluted alamarBlue solution, washed and incubated with a solution containing 6.5 mM Na 2 CO 3 , 18.5 mM NaHCO 3 , 2 mM MgCl 2 and phosphatase substrate (Sigma-Aldrich). ALP activity was measured by a spectrophotometer (Thermo).
Osteoclast culture and differentiation. Murine BM cells were flushed from the femur and tibia of mice and cultured in petri dishes in α -MEM medium with 10% FBS and 20 ng ml −1 rM-CSF. Nonadherent cells were replated into tissue culture dishes and cultured in the same medium for 3 d to obtain osteoclast precursors. The osteoclast precursors then differentiated into osteoclasts in the presence of human RANKL (50 ng ml −1 ; PeproTech) and M-CSF for 3 d. Peripheral blood mononuclear cells from the whole blood of healthy volunteers were isolated by density gradient centrifugation using Ficoll (Invitrogen, Carlsbad, CA, USA). CD14 + cells were purified from fresh PBMCs using anti-CD14 magnetic beads (Miltenyi Biotec, Auburn, CA, USA), as recommended by the manufacturer. Human monocytes were cultured in α -MEM with 10% FBS in the presence of M-CSF (20 ng ml −1 ; PeproTech, Rocky Hill, NJ, USA) for 2 d to obtain monocytederived macrophages. Experiments with human cells were approved by the Hospital for Special Surgery Institutional Review Board.
Endothelial cell culture and functional assays. Mouse BM-derived late-stage EPOCs were obtained from BioChain (7030031) and cultured in growth medium (BioChain Z7030035) as described previously 3 . Endothelial cell migration assay was set up in transwell 24-well plates with 8-μ m pore filters. In brief, 1 × 10 5 cells per well after 1-h serum starvation were seeded in the upper chamber, then incubated with conditioned medium from osteoblasts and control in the lower chambers for a further 3 h. The cells in the upper surface of each filter were removed with cotton swabs. The cells that migrated into the lower surface were fixed with 4% PFA for 30 min and then stained with crystal violet. The cell numbers were quantified by counting a centered microscope field per each filter (five wells for each condition). Endothelial cell wound healing assays were conducted in 12-well plates precoated with gelatin (STEMCELL Technologies). A total of 3 × 10 5 cells per well were plated overnight and stimulated with a wound in the form of a single linear scratch made with a yellow pipette tip. After gently washing the well twice, cells were cultured in medium with SLIT3 or vehicle. At 6 and 12 h after injury, cells were stained by 0.5% crystal violet and photographed. The width of the wound area was quantitatively evaluated using ImageJ (http:// rsb.info.nih.gov/ij/download.html). Endothelial cell proliferation assays were conducted in 96-well plates precoated with gelatin (STEMCELL Technologies). EPOCs (3 × 10 4 cells per well) were seeded in the medium with a serial dilution of SLIT3 protein or vehicle in plates. At 0, 24, and 48 h after seeding, cells were incubated with tenfold diluted alamarBlue solution (Thermo Fisher), and the supernatant was evaluated with a spectrophotometer (Thermo) (five wells for each condition). Endothelial cell tube formation assay was conducted in 96-well plates precoated with Matrigel (BD). After 1-h serum starvation, EPOCs (3 × 10 4 cells per well) were seeded in conditioned medium dilution or control medium on polymerized Matrigel in plates. After 5-h incubation at 37 °C, the number of tube branches in each well was observed and quantified by counting four random fields per well with microscopy (five wells for each condition).
Quantitative real-time PCR analysis. Total RNA was extracted using TRIzol reagent (Invitrogen) or RNeasy Mini Kit (Qiagen), and reverse transcription was performed with the High-Capacity cDNA Reverse Transcription Kit from Applied Biosystems according to the manufacturer's instructions. We performed quantitative analysis of gene expression using SYBR Green PCR Master Mix (Applied Biosystems) with the Mx3000P real-time PCR system (Agilent Technologies). Hprt expression was used as an internal control. The primers used for PCR are described in Supplementary Table 1 .
RNA sequencing and analysis. Reads were aligned to the mm9 mouse transcripts using STAR (version 2.3.0e) 44 with default parameters, and resulting bam files were sorted and indexed using samtools. Gene counts were obtained by applying feature counts (version 1.4.3) 45 to sorted bam files, and only unique-mapping reads were used. Genes without any expression counts in any sample were discarded. The DESeq2 (version 1.4.5) R package 46 was used to normalize gene count data and then detect DEGs between mutant mice and control groups with false discovery rate < 0.1 and absolute log2 fold change > 0.5. Mosaic version 1.1 was used to retrieve GO information for all genes of the mouse genome 47 . We performed functional analysis on DEGs with DAVID 48 (version 6.7), and biological process GO terms with enrichment P < 0.05 were selected as overrepresented functions.
Western blot analysis. We performed Western blot analysis according to a previously described standard protocol 49 . Primary antibodies were specific for SLIT3 (1:500; AF3629; R&D Systems), ROBO1 (1:500; ab7279; Abcam), ROBO2 (1:1000; ab75014; Abcam), YAP (1:1,000; 4912; Cell Signaling), p-YAP (1:1,000; 4911; Cell Signaling), AKT (1:1,000; 4691; Cell Signaling), p-AKT (1:1,000; 4060; Cell Signaling), ERK (1:1,000; 9102; Cell Signaling), p-ERK (1:1,000; 9101; Cell Signaling), and beta-actin (1:5,000; sc-47778; Santa Cruz) or Hsp90 (1:1000; sc-13119; Santa Cruz). Secondary anti-mouse/rabbit HRP-conjugated antibodies were subsequently applied.
ELISA analysis. We analyzed SLIT3 ELISA (Lifespan LS-F7173) and CTX ELISA (Lifespan LS-F21349) by using a kit. All ELISA assays were run according to the manufacturer's instructions.
Bone fracture model. All surgical procedures were performed under isoflurane (1-4%) anesthesia via nosecone. Surgical sites were sterilized using a betadine/ iodide/isopropanol prep after hair removal by a clipper with a #40 blade and depilatory cream (Nair). After surgery, the visceral lining or muscle was sutured with absorbable Ethicon Vicryl sutures (Cat #95057-014; VWR) before closing the skin with wound clips that were then removed 2 weeks postoperatively. Animals received intraperitoneal Buprenex (0.5 mg kg −1 ) and oral meloxicam (2.0 mg kg −1 ) as analgesia before surgery and once every 24 h postsurgery for 3 days. All surgical procedures are approved by the Institutional Animal Care and Use Committee of Weill Cornell Medical College (Protocol 2012-0005).
Bone fracture was done following previously described protocols with modifications 50 . In brief, after anesthesia and surgical site sterilization, an incision above the right anterolateral femur was made. The femur and patella were then exposed and a 27-gauge syringe needle was inserted parallel with the long axis of the femur through the patellar groove into the marrow cavity. The needle was then removed, and a single cut was made in the middle of the femoral diaphysis using a Dremel saw with a diamond thin cutting wheel (Cat. #100230-724; VWR). A blunt 25-gauge needle was then inserted into the marrow space through the hole made in the patella to stabilize the fracture. The needle was then trimmed to avoid it from projecting into the patella-femoral joint space. Muscle was then placed over the osteotomy site and stitched with absorbable sutures before closing the skin with wound clips.
When assessing the therapeutic effects of SLIT3, 1 mg kg −1 body weight of SLIT3 recombinant protein (R&D Systems) or vehicle was i.v. injected to the mice twice per week for 3 weeks after the surgery. Alternatively, the gelatin sponge was manually soaked with SLIT3 (300 μ g ml −1 in PBS) or vehicle for 1 h on ice and immediately placed to the surgical fracture area. All animals were euthanized by CO 2 at time points indicated.
Ovariectomy-induced bone loss.
For the prophylactic model, 12-week-old female mice (JAX) were anesthetized and bilaterally ovariectomized or sham operated. Ovariectomized mice were given twice weekly i.v. injections of 1 mg kg −1 body weight of SLIT3 or vehicle, or daily subcutaneous injections of 80 μ g kg −1 PTH (1-34) for 6 weeks starting 2 weeks after OVX. For the model where SLIT3 was delivered in a therapeutic manner after osteopenia onset, OVX was performed in 12-week-old mice; mice were observed for 8 weeks post-OVX to allow for onset of osteopenia, and then mice were treated with SLIT3 (1 mg kg −1 ) or vehicle for 6 further weeks. All mice were then randomly assigned to one of four groups: sham, OVX + vehicle, OVX + SLIT3 and OVX + PTH. Three days after the last injection, all of the mice were euthanized and subjected to bone analysis as described earlier.
Biomechanical analysis. All bones were tested to failure using four-point bending on a precision electromagnetic-based load frame (EnduraTEC ELF 3200; Bose Corporation, Minnetonka, MN, USA). Femurs were placed with the posterior surface on the lower supports, spaced 9.9 mm apart. The upper supports were spaced 3.3 mm. Load was applied at a rate of 0.1 mm s −1 until failure occurred. The failure load (N) and bending stiffness (N mm −2 ) within the elastic range were calculated from the force-displacement curves and the four-point dimensions.
Human bone callus collection. The project was approved by the Ethics Committee of Shaoxing People's Hospital (No. 080), and the protocol was carried out in accordance with approved guidelines. Preoperative informed consent was obtained from each patient. From January 2010 to June 2014, bone callus samples were obtained from patients undergoing surgical treatment in the Department of Orthopedics of Shaoxing People's Hospital. Callus was collected from patients who required surgical treatment for failure of skeletal traction.
Inclusion criteria were as follows: (1) surgeries after failure of conservative treatment or external fixation were applied temporarily before open reduction and plate fixation for long bone fractures; (2) secondary surgeries after failure of internal fixation, including loosened or broken plates or screws, bent or broken intramedullary nails, and fracture angulation and aversion abnormalities; and (3) secondary surgeries for hypertrophic non-union. Exclusion criteria were as follows: (1) fracture complicated with microbial infection; (2) fracture complicated with brain injury; (3) bone tumors; (4) systemic bone-related diseases; and (5) patients treated with hormones, steroids, vitamin D or calcium. Further demographic information has been published elsewhere 51 .
Statistical methods. All data were presented as the mean ± s.e.m. Sample sizes were calculated on the assumption that a 30% difference in the parameters measured would be considered biologically significant with an estimate of sigma of 10-20% of the expected mean. Alpha and Beta were set to the standard values of 0.05 and 0.8, respectively. No animals or samples were excluded from analysis, and where applicable, animals were randomized to treatment versus control groups. Statistical methods are indicated in the figure legends. The GraphPad PRISM software (v6.0a; GraphPad, La Jolla, CA, USA) was used for statistical analysis. A P value < 0.05 was considered statistically significant: *P < 0.05; **P < 0.01; ***P < 0.001. Corresponding author(s): Matthew Greenblatt Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
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Experimental design 1. Sample size
Describe how sample size was determined.
Generally, sample sizes were calculated on the assumption that a 30% difference in the parameters measured would be considered biologically significant with an estimate of sigma of 10-20% of the expected mean. Alpha and Beta were set to the standard values of .05 and 0.8, respectively.
Data exclusions
Describe any data exclusions.
No animals or samples were excluded from analysis.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
Experiments were repeated 2 times to ensure reproducibility except where otherwise indicated in the figure legends.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For all experiments utilizing SLIT3 treatment of mice, mice were randomized to SLIT3 or vehicle treatment. Where applicable, mice were randomized to treatment with tamoxifen or vehicle.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Investigators performing uCT or histomorphometry analysis were blinded to the genotype and treatment group of each sample. Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated The statistical test(s) used and whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section. Describe the software used to analyze the data in this study.
GraphPad Prism and Microsoft Excel
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party.
There are no restrictions
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines 11. Description of research animals Provide all relevant details on animals and/or animal-derived materials used in the study.
Shn3-/-(BALB/c), Shn3KI/KI (C57BL/6j), Shn3 floxed allele (C57BL/6j), Slit3-/-(BALB/c), Robo1-/-(ICR) and Robo4-/-(C57BL/6j) mice were all previously reported, with Robo1-/-mice being a generous gift from Dr. Marc Tessier- Lavigne 4, 7, 8, 14, 19, 40. To generate Slit3 floxed mice, the SLIT3-F08 mouse embryonic stem (ES) cell line in which exon 8 is flanked by loxP sites was obtained from International Mouse Phenotyping Consortium (IMPC). After validation, F08 EC cells were injected into C57BL/6J blastocysts, and the derived chimeras displaying germline transmissions were selected for further breeding. The LacZ and neo cassettes were removed by intercrossing with transgenic mice expressing Flp recombinase. Slit3 floxed mice were backcrossed with C57BL/6j mice for 8 generations. Transgenic mice expressing Cre recombinase under control of the cdh5 promoter (cdh5-Cre) 41, osterix promoter (osx-Cre) 42 , dmp1 promoter (dmp1-Cre) 43 and Osteocalcin-CreERT mice44 were mated with Shn3 floxed mice or Slit3 floxed mice to obtain various Shn3 or Slit3 conditional KO mouse. For postnatal activation of CreERT, 100mg/kg tamoxifen (Sigma) in corn oil (Sigma) was intraperitoneally injected to 1 month-old mice once a day for five consecutive days. Littermate controls were utilized for all experiments. All animals were maintained in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were handled according to protocols approved by the Weill Cornell Medical College subcommittee on animal care (IACUC).
For the prophylactic OVX model, 12-week-old female mice (JAX, C57BL/6j) were anesthetized and bilaterally ovariectomized or sham operated. Ovariectomized mice were given twice weekly intravenous injections of 1mg per kg body weight of SLIT3 or vehicle or daily sc injections of 80ug/kg PTH (1-34) for 6 weeks starting 2 weeks after ovariectomy . For the model where SLIT3 was delivered in a therapeutic manner after osteopenia onset, OVX was performed in 12 week old mice, mice were observed for 8 weeks post-OVX to allow for onset of osteopenia, and then mice were treated with SLIT3 (1mg/kg) or vehicle for 6 further weeks.
For fracture model, 5 week old mice of the indicated genotypes underwent fracture as described in the methods section. 
